Top News

Montigen Acquired For $18M



Salt Lake City, Utah-based Montigen Pharmaceuticals has been acquired by SuperGen for $18M. Montigen is developing pharmaceuticals for the treatment of cancer. The deal also includes earn out of up to $22M in stock contingent on achieving specific regulatory milestones. The deal included $9M in cash and $9M in shares of SuperGen, which is listed on the Nasdaq as SUPG. SuperGen said that the acquisition would expand its position in the oncology and hematology markets. SuperGen last received a venture round from undisclosed investors. The companies said that Montigen's founder, Dr. David J. Bearss will join SuperGen, along with Montigen's 12 research team in Salt Lake.


 

Marketplace

 

 

Latest Headlines

Browse Issues